Global Intratumoral Cancer Therapies Market Report and Forecast 2025-2034

Intratumoral Cancer Therapies Market Size

The global intratumoral cancer therapies market size was valued at USD 189.73 billion in 2023, driven by the rising prevalence of cancer diseases and the geriatric population across the globe. The market is expected to grow at a CAGR of 10% during the forecast period of 2024-2032, with the values likely to rise from USD 208.62 billion in 2024 to USD 445.77 billion by 2032.

Intratumoral Cancer Therapies Market Outlook

• The demand for intratumoral cancer therapies is influenced by the rising preference for combination therapies and personalised treatment to combat the increasing incidence of cancer.

• In April 2024, the phase I clinical trial of SYNC-T, an investigational intratumoral therapy, demonstrated significant response rates and minimal toxicity in the management of metastatic castrate-resistant prostate cancer. Increased R&D initiatives are expected to boost the market growth positively.

• North America is expected to have the largest market share because of the well-developed healthcare system and high investments in medical technology, while Asia Pacific is expected to register a high growth rate in the forecast period.

Intratumoral Cancer Therapies Market Overview

Cancer is a leading cause of death that originates from cells multiplying and invading other tissues and organs. Intratumoral therapy involves deploying antibodies into the tumor mass to trigger and strengthen an antitumor immune response. It stimulates local immunity against the tumor by utilizing it as the source of its vaccine. It also stimulates adaptive, polyclonal immunity against clinically established tumor-specific antigens (TSA) or tumor-associated antigens (TAA).

Intratumoral Cancer Therapies Market Growth Drivers

Rising Prevalence of Cancer Fuels the Market Growth

Rising cases of breast, lung, colorectal, and prostate, among others, are prompting the need for novel and effective treatments. For instance, the American Cancer Society  estimates 152,810 new cases of colorectal cancer in 2024. According to their estimates, 81,540 men and 71,270 women will be diagnosed with the disease. Around 106,590 cases will be colon cancer, and 46,220 cases will be diagnosed as rectal cancer, respectively. Accordingly, a sustained rise in cancer rates is expected to fuel the market for these revolutionary treatment approaches.

Intratumoral Cancer Therapies Market Trends

Rising Preference for Combination Therapies

Combination therapy when used in conjugation with immunotherapy, chemotherapy, and radiation therapy may enhance therapeutic effectiveness and patient outcomes, and it is becoming more and more common. The synergistic effects of this approach are being investigated in clinical trials.

Development of Novel Therapeutic Agents

The market is witnessing the development of innovative treatments such as oncolytic viruses, immune checkpoint inhibitors, and gene therapies to broaden the range of tools for intra-tumoural cancer treatment. Such developments are expected to boost market growth and improve patient outcomes in the forecast period.

Technological Advancements in Drug Delivery Systems

Advancements in nanotechnology, biodegradable polymers, and targeted delivery systems improve the selectivity and efficiency of intratumoral cancer treatments. These technologies help maintain optimal drug levels, enhancing efficacy, increasing treatment options, and driving demand in the market.

Increasing Focus on Personalized Medicine

The global intratumoral cancer therapies market is rapidly shifting towards utilizing patient characteristics like genetic makeup, tumor type, and response to previous treatment. Development in genomics and proteomics biomarkers enhance treatment quality for patients while reducing treatment-related side effects.

Recent Developments in the Intratumoral Cancer Therapies Market

In April 2024 , the American Association for Cancer Research (AACR) Annual Meeting 2024 highlighted the potential of SYNC-T, an investigational therapy that applies device-induced vaccination at the tumor site with concurrent intratumoral administration of a multitarget biologic agent for managing metastatic castrate-resistant prostate cancer. In a phase I clinical trial, the drug achieved an objective response in 11 out of 13 evaluable patients and had only mild to moderate toxicity in patients, which was lower than intravenous immunotherapies.

In January 2022 , Bristol-Myers Squibb announced that the Japanese Ministry of Health, Labour, and Welfare approved Abecma, which is a B-cell maturation antigen (BCMA)-directed chimeric antigen receptor (CAR) T cell immunotherapy, for use in adults with relapsed and refractory multiple myeloma who have undergone at least three prior therapies. Abecma was the first licensed CAR T cell therapy for treating R/R multiple myeloma in Japan.

Intratumoral Cancer Therapies Market Segmentation

Market Breakup by Type
 

• Monoclonal Antibodies

• Vaccines

• Checkpoint Inhibitors

• Cell Therapies

• Immune System Modulators

• Adoptive Cell Transfer

• Cytokines

• Others

Market Breakup by Application

• Lung Cancer

• Breast Cancer

• Colorectal Cancer

• Melanoma

• Prostate Cancer

• Head & Neck Cancer

• Others

Market Breakup by End Use

• Hospitals

• Cancer Research Centers

• Clinics

• Others

Market Breakup by Region

• North America

• Europe

• Asia Pacific

• Latin America

• Middle East and Africa

Intratumoral Cancer Therapies Market Share

Monoclonal Antibodies Hold a Substantial Market Share Based on the Type

Based on type, the market is divided into monoclonal antibodies, vaccines, checkpoint inhibitors, cell therapies, immune system modulators, adoptive cell transfer, cytokines, and others. Among these, monoclonal antibodies are expected to dominate the market as they have higher specificity towards tumor tissues, thus, while destroying malignant cells, they do not affect the systemically healthy cells. Monoclonal antibodies have become the gold standard in precision medicine, leading to more clinical studies of targeted therapies.

Market Segmentation by Application Set to Witness Substantial Growth

Based on application, the market is segmented into lung cancer, breast cancer, colorectal cancer, melanoma, prostate cancer, head & neck cancer, and others. Among these, lung cancer is expected to dominate the market due to high incidence of the disease. Intratumoral therapies are increasing in popularity as they enable the delivery of high concentrations of therapeutic agents to the tumor mass with minimal systemic toxicity. This approach is therefore valuable as an alternative to traditional therapies, fostering the advancements of new personalized cancer treatments and expanding the array of targeted therapy options for other cancers.

Intratumoral Cancer Therapies Market Analysis by Region

Based on the region, the market is divided into North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa. Of these regions, North America is expected to dominate, owing to its developed healthcare system, high spending on healthcare, and its leading investment in modern, advanced medical technologies.

Due to the increasing incidence of cancer, better infrastructure, and focus on research, the fastest growth is expected to be seen in the Asia-Pacific region. Countries like China, Japan, and India are expected to lead the market share in the region.

Leading Players in the Intratumoral Cancer Therapies Market

The key features of the market report include patent analysis, clinical trial analysis, grants analysis, funding and investment analysis, and strategic initiatives by the leading players. The major companies are:

Amgen Inc.

The company was established in 1980 and is based in California, USA. It offers T-VEC (talimogene laherparepvec), an oncolytic viral therapy genetically engineered for melanoma treatment.

AstraZeneca

It is a UK-based company and has a well-established portfolio of immune-oncology assets, including combinations that can be delivered intratumorally.

Bayer AG

This company was founded in 1863 and is headquartered in Germany. Some of the intratumoral cancer therapy activities consist of developing new drug delivery systems coupled with combination therapy to boost the effectiveness of their current cancer treatment drugs.

B. Bristol-Myers Squibb Company

It was founded in 1887 and headquartered in New York, USA. Opdivo and Yervoy are the two main products provided by the company, while these agents are mainly used in combination with other products for increased effectiveness.

Other companies include Pfizer Inc., Novartis AG, Johnson & Johnson, Eli Lilly Company, Cybrexa, and Novocure GmbH, among others.

Kindly note that this only represents a partial list of companies. The complete list will be provided in the report.

Key Highlights of the Report

Key Questions Answered in the Intratumoral Cancer Therapies Market

• What was the global Intratumoral cancer therapies market value in 2023?
• What is the global Intratumoral cancer therapies market forecast outlook for 2024-2032?
• What are the regional markets covered in the EMR report?
• What are the major factors aiding the global Intratumoral cancer therapies market demand? 
• What are the market's major drivers, opportunities, and restraints? 
• Which regional market is expected to lead the market share in the forecast period? 
• Which country is expected to experience expedited growth during the forecast period? 
• What are the major global Intratumoral cancer therapies market trends?
• How does the rise in the geriatric population impact the market size?
• Who are the key players involved in the Intratumoral cancer therapies market?
• What are the current unmet needs and challenges in the market?
• How are partnerships, collaborations, mergers, and acquisitions among the key market players shaping the market dynamics?
• What is the market segmentation based on type?
• What are the current advancements in monoclonal antibodies for intratumoral cancer therapies?
• What other novel intratumoral cancer therapies are emerging in the market?
• What is the market breakup based on application?
• What is the effectiveness of intratumoral therapies for head and neck cancer?
• What is the market breakup based on the end user?
• How are hospitals integrating intratumoral cancer therapies into their treatment protocols? 
• What is the market breakup based on the region?
• What are the leading trends in intratumoral cancer therapies in North America?
• What is the growth potential for intratumoral cancer therapies in the Asia Pacific region?